Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 464

1.

Mixed methods process evaluation of an enhanced community-based rehabilitation intervention for elderly patients with hip fracture.

Roberts JL, Pritchard AW, Williams M, Totton N, Morrison V, Din NU, Williams NH.

BMJ Open. 2018 Aug 8;8(8):e021486. doi: 10.1136/bmjopen-2018-021486.

2.

Valproate augments Niraparib killing of tumor cells.

Booth L, Roberts JL, Rais R, Poklepovic A, Dent P.

Cancer Biol Ther. 2018 Jun 20:1-12. doi: 10.1080/15384047.2018.1472190. [Epub ahead of print]

PMID:
29923797
3.

Hip fracture in the elderly multidisciplinary rehabilitation (FEMuR) feasibility study: testing the use of routinely collected data for future health economic evaluations.

Williams NH, Mawdesley K, Roberts JL, Din NU, Totton N, Charles JM, Hoare Z, Edwards RT.

Pilot Feasibility Stud. 2018 May 7;4:76. doi: 10.1186/s40814-018-0269-5. eCollection 2018.

4.

Preferences of older patients regarding hip fracture rehabilitation service configuration: A feasibility discrete choice experiment.

Charles JM, Roberts JL, Ud Din N, Williams NH, Yeo ST, Edwards RT.

J Rehabil Med. 2018 Jul 17;50(7):636-642. doi: 10.2340/16501977-2350.

5.

Enterococcus faecalis Demonstrates Pathogenicity through Increased Attachment in an Ex Vivo Polymicrobial Pulpal Infection.

Nishio Ayre W, Melling G, Cuveillier C, Natarajan M, Roberts JL, Marsh LL, Lynch CD, Maillard JY, Denyer SP, Sloan AJ.

Infect Immun. 2018 Apr 23;86(5). pii: e00871-17. doi: 10.1128/IAI.00871-17. Print 2018 May.

PMID:
29483293
6.

[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration.

Booth L, Roberts JL, Rais R, Kirkwood J, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Poklepovic A, Dent P.

Oncotarget. 2017 Dec 26;9(5):6062-6074. doi: 10.18632/oncotarget.23681. eCollection 2018 Jan 19.

7.

Transcriptional Mechanisms of Secondary Fracture Healing.

Roberts JL, Paglia DN, Drissi H.

Curr Osteoporos Rep. 2018 Apr;16(2):146-154. doi: 10.1007/s11914-018-0429-9. Review.

PMID:
29441447
8.

Unconventional Approaches to Modulating the Immunogenicity of Tumor Cells.

Booth L, Roberts JL, Kirkwood J, Poklepovic A, Dent P.

Adv Cancer Res. 2018;137:1-15. doi: 10.1016/bs.acr.2017.11.004. Epub 2018 Jan 3.

PMID:
29405973
9.

The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.

Booth L, Roberts JL, Samuel P, Avogadri-Connors F, Cutler RE, Lalani AS, Poklepovic A, Dent P.

Cancer Biol Ther. 2018 Jun 3;19(6):525-533. doi: 10.1080/15384047.2018.1436024. Epub 2018 Mar 6.

PMID:
29405820
10.

TP53 is required for BECN1- and ATG5-dependent cell death induced by sphingosine kinase 1 inhibition.

Lima S, Takabe K, Newton J, Saurabh K, Young MM, Leopoldino AM, Hait NC, Roberts JL, Wang HG, Dent P, Milstien S, Booth L, Spiegel S.

Autophagy. 2018;14(6):942-957. doi: 10.1080/15548627.2018.1429875. Epub 2018 Mar 11.

PMID:
29368980
11.

Observation of a strong-coupling effect on electron-ion collisions in ultracold plasmas.

Chen WT, Witte C, Roberts JL.

Phys Rev E. 2017 Jul;96(1-1):013203. doi: 10.1103/PhysRevE.96.013203. Epub 2017 Jul 7.

PMID:
29347164
12.

The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.

Booth L, Roberts JL, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Poklepovic A, Dent P.

Cancer Biol Ther. 2018 Mar 4;19(3):239-247. doi: 10.1080/15384047.2018.1423927. Epub 2018 Jan 22.

PMID:
29333953
13.

Curcumin interacts with sildenafil to kill GI tumor cells via endoplasmic reticulum stress and reactive oxygen/ nitrogen species.

Roberts JL, Poklepovic A, Booth L.

Oncotarget. 2017 Aug 2;8(59):99451-99469. doi: 10.18632/oncotarget.19807. eCollection 2017 Nov 21.

14.

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.

Booth L, Roberts JL, Poklepovic A, Kirkwood J, Sander C, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Dent P.

Cancer Biol Ther. 2018 Feb 1;19(2):132-137. doi: 10.1080/15384047.2017.1394556. Epub 2017 Dec 8.

15.

HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo.

Booth L, Roberts JL, Poklepovic A, Avogadri-Connors F, Cutler RE, Lalani AS, Dent P.

Oncotarget. 2017 Oct 9;8(52):90262-90277. doi: 10.18632/oncotarget.21660. eCollection 2017 Oct 27.

16.

HDAC inhibitors enhance the immunotherapy response of melanoma cells.

Booth L, Roberts JL, Poklepovic A, Kirkwood J, Dent P.

Oncotarget. 2017 May 17;8(47):83155-83170. doi: 10.18632/oncotarget.17950. eCollection 2017 Oct 10.

17.

Development of an evidence-based complex intervention for community rehabilitation of patients with hip fracture using realist review, survey and focus groups.

Roberts JL, Din NU, Williams M, Hawkes CA, Charles JM, Hoare Z, Morrison V, Alexander S, Lemmey A, Sackley C, Logan P, Wilkinson C, Rycroft-Malone J, Williams NH.

BMJ Open. 2017 Oct 11;7(10):e014362. doi: 10.1136/bmjopen-2016-014362.

18.

Patient Factors Associated with Shorter Length of Stay Following Total Hip Arthroplasty-A Retrospective Cohort Study.

Byrne PA, Gupta S, Hopper GP, Deakin AH, Roberts JL, Kinninmonth AWG.

Surg Technol Int. 2017 Oct 12;31:197-200.

PMID:
29020708
19.

Developing a multidisciplinary rehabilitation package following hip fracture and testing in a randomised feasibility study: Fracture in the Elderly Multidisciplinary Rehabilitation (FEMuR).

Williams NH, Roberts JL, Din NU, Charles JM, Totton N, Williams M, Mawdesley K, Hawkes CA, Morrison V, Lemmey A, Edwards RT, Hoare Z, Pritchard AW, Woods RT, Alexander S, Sackley C, Logan P, Wilkinson C, Rycroft-Malone J.

Health Technol Assess. 2017 Aug;21(44):1-528. doi: 10.3310/hta21440.

20.

[pemetrexed + sildenafil], via autophagy-dependent HDAC downregulation, enhances the immunotherapy response of NSCLC cells.

Booth L, Roberts JL, Poklepovic A, Dent P.

Cancer Biol Ther. 2017 Sep 2;18(9):705-714. doi: 10.1080/15384047.2017.1362511.

PMID:
28812434
21.

Antibiotic utilisation in very low birth weight infants without sepsis or necrotising enterocolitis is associated with multiple adverse outcomes.

Roberts JL, Patel RM.

Evid Based Med. 2017 Oct;22(5):187. doi: 10.1136/ebmed-2017-110756. Epub 2017 Jul 12. No abstract available.

PMID:
28701373
22.

Negotiating Commercial Interests in Biospecimens.

Roberts JL.

J Law Med Ethics. 2017 Mar;45(1):138-141. doi: 10.1177/1073110517703107.

PMID:
28661280
23.

Clinical Care Guideline for Improving Pediatric Acute Musculoskeletal Infection Outcomes.

Spruiell MD, Searns JB, Heare TC, Roberts JL, Wylie E, Pyle L, Donaldson N, Stewart JR, Heizer H, Reese J, Scott HF, Pearce K, Anderson CJ, Erickson M, Parker SK.

J Pediatric Infect Dis Soc. 2017 Sep 1;6(3):e86-e93. doi: 10.1093/jpids/pix014.

PMID:
28419275
24.

The Impact of Nutritional Interventions beyond the First 2 Years of Life on Linear Growth: A Systematic Review and Meta-Analysis.

Roberts JL, Stein AD.

Adv Nutr. 2017 Mar 15;8(2):323-336. doi: 10.3945/an.116.013938. Print 2017 Mar. Review.

25.

The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.

Booth L, Roberts JL, Sander C, Lee J, Kirkwood JM, Poklepovic A, Dent P.

Oncotarget. 2017 Mar 7;8(10):16367-16386. doi: 10.18632/oncotarget.14829.

26.

PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib].

Booth L, Roberts JL, Poklepovic A, Dent P.

Oncotarget. 2017 Feb 21;8(8):13464-13475. doi: 10.18632/oncotarget.14562.

27.

Should you profit from your genome?

Roberts JL, Pereira S, McGuire AL.

Nat Biotechnol. 2017 Jan 10;35(1):18-20. doi: 10.1038/nbt.3757. No abstract available.

PMID:
28072771
28.

Cucurbit[7]uril-Tetramethylrhodamine Conjugate for Direct Sensing and Cellular Imaging.

Bockus AT, Smith LC, Grice AG, Ali OA, Young CC, Mobley W, Leek A, Roberts JL, Vinciguerra B, Isaacs L, Urbach AR.

J Am Chem Soc. 2016 Dec 21;138(50):16549-16552. doi: 10.1021/jacs.6b11140. Epub 2016 Dec 8.

PMID:
27998093
29.

The Legality of Biometric Screening of Professional Athletes.

Roberts JL, Cohen IG, Deubert CR, Lynch HF.

Am J Bioeth. 2017 Jan;17(1):65-67. No abstract available.

PMID:
27996898
30.

AR-12 Inhibits Chaperone Proteins Preventing Virus Replication and the Accumulation of Toxic Misfolded Proteins.

Booth L, Roberts JL, Ecroyd H, Reid SP, Proniuk S, Zukiwski A, Jacob A, Damonte E, Tuñón MJ, Dent P.

J Clin Cell Immunol. 2016 Oct;7(5). pii: 454. Epub 2016 Sep 16. No abstract available.

31.

PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide.

Booth L, Roberts JL, Poklepovic A, Gordon S, Dent P.

Oncotarget. 2017 Jan 3;8(1):1449-1468. doi: 10.18632/oncotarget.13640.

32.

Reactive gamma-ketoaldehydes as novel activators of hepatic stellate cells in vitro.

Longato L, Andreola F, Davies SS, Roberts JL, Fusai G, Pinzani M, Moore K, Rombouts K.

Free Radic Biol Med. 2017 Jan;102:162-173. doi: 10.1016/j.freeradbiomed.2016.11.036. Epub 2016 Nov 24.

PMID:
27890721
33.

Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo.

Booth L, Albers T, Roberts JL, Tavallai M, Poklepovic A, Lebedyeva IO, Dent P.

Oncotarget. 2016 Jun 28;7(26):40398-40417. doi: 10.18632/oncotarget.9752.

34.

Fracture in the Elderly Multidisciplinary Rehabilitation (FEMuR): a phase II randomised feasibility study of a multidisciplinary rehabilitation package following hip fracture.

Williams NH, Roberts JL, Din NU, Totton N, Charles JM, Hawkes CA, Morrison V, Hoare Z, Williams M, Pritchard AW, Alexander S, Lemmey A, Woods RT, Sackley C, Logan P, Edwards RT, Wilkinson C.

BMJ Open. 2016 Oct 5;6(10):e012422. doi: 10.1136/bmjopen-2016-012422.

35.

What to Expect When [Your Employer Suspects] You're Expecting.

Morain SR, Fowler LR, Roberts JL.

JAMA Intern Med. 2016 Nov 1;176(11):1597-1598. doi: 10.1001/jamainternmed.2016.5268. No abstract available.

PMID:
27598656
36.

The benefits of errorless learning for people with amnestic mild cognitive impairment.

Roberts JL, Anderson ND, Guild E, Cyr AA, Jones RSP, Clare L.

Neuropsychol Rehabil. 2018 Sep;28(6):984-996. doi: 10.1080/09602011.2016.1216000. Epub 2016 Aug 8.

PMID:
27499240
37.

Rationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor Therapeutic.

Tavallai M, Booth L, Roberts JL, Poklepovic A, Dent P.

Front Oncol. 2016 Jun 13;6:142. doi: 10.3389/fonc.2016.00142. eCollection 2016.

38.

Functional properties of spinach (Spinacia oleracea L.) phytochemicals and bioactives.

Roberts JL, Moreau R.

Food Funct. 2016 Aug 10;7(8):3337-53. doi: 10.1039/c6fo00051g. Epub 2016 Jun 29. Review.

PMID:
27353735
39.

Repeated large-scale retreat and advance of Totten Glacier indicated by inland bed erosion.

Aitken AR, Roberts JL, van Ommen TD, Young DA, Golledge NR, Greenbaum JS, Blankenship DD, Siegert MJ.

Nature. 2016 May 19;533(7603):385-9. doi: 10.1038/nature17447.

40.

AR-12 Inhibits Multiple Chaperones Concomitant With Stimulating Autophagosome Formation Collectively Preventing Virus Replication.

Booth L, Roberts JL, Ecroyd H, Tritsch SR, Bavari S, Reid SP, Proniuk S, Zukiwski A, Jacob A, Sepúlveda CS, Giovannoni F, García CC, Damonte E, González-Gallego J, Tuñón MJ, Dent P.

J Cell Physiol. 2016 Oct;231(10):2286-302. doi: 10.1002/jcp.25431. Epub 2016 Jun 6.

PMID:
27187154
41.

Dominant Splice Site Mutations in PIK3R1 Cause Hyper IgM Syndrome, Lymphadenopathy and Short Stature.

Petrovski S, Parrott RE, Roberts JL, Huang H, Yang J, Gorentla B, Mousallem T, Wang E, Armstrong M, McHale D, MacIver NJ, Goldstein DB, Zhong XP, Buckley RH.

J Clin Immunol. 2016 Jul;36(5):462-71. doi: 10.1007/s10875-016-0281-6. Epub 2016 Apr 13.

42.

[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling.

Booth L, Roberts JL, Tavallai M, Chuckalovcak J, Stringer DK, Koromilas AE, Boone DL, McGuire WP, Poklepovic A, Dent P.

Oncotarget. 2016 Apr 26;7(17):23608-32. doi: 10.18632/oncotarget.8281.

43.

Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS.

Tavallai M, Booth L, Roberts JL, McGuire WP, Poklepovic A, Dent P.

Oncotarget. 2016 Apr 5;7(14):17290-300. doi: 10.18632/oncotarget.8039.

44.

The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling.

Booth L, Roberts JL, Tavallai M, Webb T, Leon D, Chen J, McGuire WP, Poklepovic A, Dent P.

Oncotarget. 2016 Apr 12;7(15):19620-30. doi: 10.18632/oncotarget.7746.

45.

Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function.

Booth L, Shuch B, Albers T, Roberts JL, Tavallai M, Proniuk S, Zukiwski A, Wang D, Chen CS, Bottaro D, Ecroyd H, Lebedyeva IO, Dent P.

Oncotarget. 2016 Mar 15;7(11):12975-96. doi: 10.18632/oncotarget.7349.

46.

In Vitro Evaluation of the Interaction of Dextrin-Colistin Conjugates with Bacterial Lipopolysaccharide.

Roberts JL, Cattoz B, Schweins R, Beck K, Thomas DW, Griffiths PC, Ferguson EL.

J Med Chem. 2016 Jan 28;59(2):647-54. doi: 10.1021/acs.jmedchem.5b01521. Epub 2016 Jan 14.

PMID:
26730548
47.

Improvement of mTORC1-driven overproduction of apoB-containing triacylglyceride-rich lipoproteins by short-chain fatty acids, 4-phenylbutyric acid and (R)-α-lipoic acid, in human hepatocellular carcinoma cells.

Roberts JL, He B, Erickson A, Moreau R.

Biochim Biophys Acta. 2016 Mar;1861(3):166-76. doi: 10.1016/j.bbalip.2015.12.001. Epub 2015 Dec 8.

PMID:
26680362
48.

Estrogen protects against dopamine neuron toxicity in primary mesencephalic cultures through an indirect P13K/Akt mediated astrocyte pathway.

Bains M, Roberts JL.

Neurosci Lett. 2016 Jan 1;610:79-85. doi: 10.1016/j.neulet.2015.10.054. Epub 2015 Oct 28.

49.

Celecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistance.

Webb T, Carter J, Roberts JL, Poklepovic A, McGuire WP, Booth L, Dent P.

Cancer Biol Ther. 2015;16(11):1660-70. doi: 10.1080/15384047.2015.1099769. Epub 2015 Sep 29.

50.

Emerging role of alpha-lipoic acid in the prevention and treatment of bone loss.

Roberts JL, Moreau R.

Nutr Rev. 2015 Feb;73(2):116-25. doi: 10.1093/nutrit/nuu005. Review.

PMID:
26024498

Supplemental Content

Loading ...
Support Center